Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 17 03 2020
accepted: 01 03 2021
entrez: 18 3 2021
pubmed: 19 3 2021
medline: 13 10 2021
Statut: epublish

Résumé

In 2016, under its new National Adherence Guidelines (AGL), South Africa formalized an existing model of fast-track HIV treatment initiation counselling (FTIC). Rollout of the AGL included an evaluation study at 24 clinics, with staggered AGL implementation. Using routinely collected data extracted as part of the evaluation study, we estimated and compared the costs of HIV care and treatment from the provider's perspective at the 12 clinics implementing the new, formalized model (AGL-FTIC) to costs at the 12 clinics continuing to implement some earlier, less formalized, model that likely varied across clinics (denoted here as early-FTIC). This was a cost-outcome analysis using standard methods and a composite outcome defined as initiated antiretroviral therapy (ART) within 30 days of treatment eligibility and retained in care at 9 months. Using patient-level, bottom-up resource-utilization data and local unit costs, we estimated patient-level costs of care and treatment in 2017 U.S. dollars over the 9-month evaluation follow-up period for the two models of care. Resource use and costs, disaggregated by antiretroviral medications, laboratory tests, and clinic visits, are reported by model of care and stratified by the composite outcome. A total of 350/343 patients in the early-FTIC/AGL-FTIC models of care are included in this analysis. Mean/median costs were similar for both models of care ($135/$153 for early-FTIC, $130/$151 for AGL-FTIC). For the subset achieving the composite outcome, resource use and therefore mean/median costs were similar but slightly higher, reflecting care consistent with treatment guidelines ($163/$166 for early-FTIC, $168/$170 for AGL-FTIC). Not surprisingly, costs for patients not achieving the composite outcome were substantially less, mainly because they only had two or fewer follow-up visits and, therefore, received substantially less ART than patients who achieved the composite outcome. The 2016 adherence guidelines clarified expectations for the content and timing of adherence counseling sessions in relation to ART initiation. Because clinics were already initiating patients on ART quickly by 2016, little room existed for the new model of fast-track initiation counseling to reduce the number of pre-ART clinic visits at the study sites and therefore to reduce costs of care and treatment. Clinical Trial Number: NCT02536768.

Identifiants

pubmed: 33735206
doi: 10.1371/journal.pone.0248551
pii: PONE-D-20-07331
pmc: PMC7971492
doi:

Substances chimiques

Anti-HIV Agents 0

Banques de données

ClinicalTrials.gov
['NCT02536768']

Types de publication

Journal Article Randomized Controlled Trial Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0248551

Subventions

Organisme : PEPFAR
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

AIDS Res Treat. 2013;2013:941493
pubmed: 23956850
J Int AIDS Soc. 2019 Nov;22(11):e25409
pubmed: 31691521
PLoS Med. 2019 Sep 16;16(9):e1002912
pubmed: 31525187
Bull World Health Organ. 2010 Sep 1;88(9):675-80
pubmed: 20865072
BMJ Open. 2018 Jan 21;8(1):e019680
pubmed: 29358446
Trop Med Int Health. 2008 Aug;13(8):1005-15
pubmed: 18631314
Trop Med Int Health. 2010 Jun;15 Suppl 1:43-7
pubmed: 20586959
PLoS One. 2013 Jun 28;8(6):e67910
pubmed: 23840788
AIDS. 2013 Jan 14;27(2):243-50
pubmed: 23014517
PLoS One. 2017 Oct 30;12(10):e0186557
pubmed: 29084275
PLoS Med. 2011 Jul;8(7):e1001056
pubmed: 21811403
J Int AIDS Soc. 2013 Jan 02;16:18026
pubmed: 23305696
PLoS Med. 2011 Jul;8(7):e1001055
pubmed: 21811402
AIDS. 2017 Jul 17;31(11):1611-1619
pubmed: 28463879
PLoS One. 2013 Aug 28;8(8):e72444
pubmed: 24015245
J Int AIDS Soc. 2020 Jul;23(7):e25541
pubmed: 32686911
PLoS One. 2016 Dec 12;11(12):e0168118
pubmed: 27942005

Auteurs

Bruce A Larson (BA)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.

Sophie J S Pascoe (SJS)

Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Amy Huber (A)

Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Lawrence C Long (LC)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Joshua Murphy (J)

Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Jacqui Miot (J)

Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Nicole Fraser-Hurt (N)

The World Bank, Washington, DC, United States of America.

Matthew P Fox (MP)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.

Sydney Rosen (S)

Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH